Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1780209 | 1.00 | HDAC1 (0.54) | HDAC1KCNH2ALDH1A1SMN1; SMN2OPRM1 | |
| SCHEMBL1780212 | 1.00 | HDAC1 (0.54) | HDAC1KCNH2ALDH1A1SMN1; SMN2OPRM1 | |
| SCHEMBL1781969 | 0.94 | HDAC1 (0.53) | HDAC1KCNH2ALDH1A1KDM1ANR1H4 | |
| SCHEMBL3411782 | 0.94 | HDAC1 (0.53) | HDAC1KCNH2ALDH1A1KDM1ANR1H4 | |
| SCHEMBL1781968 | 0.94 | HDAC1 (0.53) | HDAC1KCNH2ALDH1A1KDM1ANR1H4 | |
| SCHEMBL1781962 | 0.94 | HDAC1 (0.53) | HDAC1KCNH2ALDH1A1KDM1ANR1H4 | |
| SCHEMBL1780117 | 0.91 | CA12 (0.51) | HDAC1KCNH2OPRM1OPRD1AKR1B10 | |
| SCHEMBL1780126 | 0.91 | CA12 (0.51) | HDAC1KCNH2OPRM1OPRD1AKR1B10 | |
| SCHEMBL8004533 | 0.91 | HDAC1 (0.51) | HDAC1KCNH2ALDH1A1SMN1; SMN2OPRM1 | |
| SCHEMBL1780125 | 0.91 | CA12 (0.51) | HDAC1KCNH2OPRM1OPRD1AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260020-B1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| EP-2628726-A1 | Hydroxamate-based inhibitors of deacetylases b | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| US-8349883-B2 | Hydroxamate-based inhibitors of deacetylases B | NOVARTIS AG (CH) | 2013-01-08 | — | — | US | disclosed |
| US-20110183964-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2011-07-28 | — | — | US | disclosed |
| US-7943652-B2 | Hydroxamate-based inhibitors of deacetylases B | NOVARTIS AG (CH) | 2011-05-17 | — | — | US | disclosed |
| US-20090247547-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247547-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885KCNH2 2802/4885ALDH1A1 238/4885 |
| US-20110183964-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885KCNH2 2802/4885ALDH1A1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.